Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 3:21 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 322 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Intradermal injection Clear all
Completed Phase 4 Interventional Results available

Bacteriostatic Normal Saline Versus Lidocaine for Intradermal Anesthesia

NCT04495868
View directory record Official record
Conditions
Chronic Pain
Interventions
Bacteriostatic Normal Saline, 1% Lidocaine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 15, 2026, 3:21 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

MicroRNA Activation of LOX-1 Mechanisms in Endometriosis

NCT05331053
View directory record Official record
Conditions
Endometriosis
Interventions
Atorvastatin
Drug
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2024
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer

NCT01696877
View directory record Official record
Conditions
Prostate Cancer Adenocarcinoma in Situ
Interventions
degarelix acetate, Cyclophosphamide, GVAX
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
21 Years and older · Male only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 28, 2019 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional

A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence

NCT02334735
View directory record Official record
Conditions
Melanoma
Interventions
DC Vaccine, Montanide Vaccine, Poly-ICLC
Biological
Lead sponsor
Nina Bhardwaj
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Results available

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Stage IV Melanoma

NCT00726739
View directory record Official record
Conditions
Stage IV Melanoma
Interventions
aldesleukin, allogeneic large multivalent immunogen vaccine
Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 28, 2017 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Results available

Trial of Lymphoseek in Intraoperative Localization of Lymph Nodes in Breast Cancer and Melanoma

NCT00671918
View directory record Official record
Conditions
Breast Cancer, Melanoma
Interventions
Lymphoseek
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
186 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Alexander City, Alabama • Birmingham, Alabama • La Jolla, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years

NCT01712984
View directory record Official record
Conditions
Influenza
Interventions
Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation, Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 64 Years
Enrollment
3,360 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
38
States / cities
Hoover, Alabama • Huntsville, Alabama • Chandler, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Results available

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

NCT01896869
View directory record Official record
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
Ipilimumab, Vaccine, FOLFIRINOX
Drug · Biological
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
3
States / cities
San Francisco, California • Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 19, 2020 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 1 Interventional

Phase I Study of Vaccination Schedule of Experimental HIV Vaccines

NCT00321061
View directory record Official record
Conditions
HIV Infections
Interventions
VRC-HIVDNA016-00, VRC-HIVADV014-00
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 15, 2026, 3:21 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Immunization With BCG Vaccine to Prevent Tuberculosis Infection

NCT04453293
View directory record Official record
Conditions
Tuberculosis Infection
Interventions
BCG (Tokyo 172) vaccine, Placebo
Biological · Drug
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
7
States / cities
New Haven, Connecticut • Washington D.C., District of Columbia • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Results available

Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor

NCT01326104
View directory record Official record
Conditions
Medulloblastoma, Neuroectodermal Tumor
Interventions
TTRNA-xALT, TTRNA-DCs
Biological
Lead sponsor
University of Florida
Other
Eligibility
Up to 30 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Terminated Phase 2 Interventional

Autologous TLPO Vaccine Basket

NCT06175221
View directory record Official record
Conditions
Tumor, Solid, Tumor Metastasis, Cancer, Tumor
Interventions
Tumor lysate, particle only (TLPO) vaccine
Biological
Lead sponsor
Elios Therapeutics, LLC
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 15, 2026, 3:21 PM EDT
Recruiting Not applicable Interventional

J-Tip Use for Paracentesis in Adults With Ascites

NCT06996379
View directory record Official record
Conditions
Evaluate Patient Comfort Level During Paracentesis by Numbing Skin With a Needle-less Device, Instead of Using a Needle to Numb the Skin
Interventions
Experimental J-Tip Needle-Free Injection System, Control (Standard treatment)
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Recruiting Phase 2 Interventional

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

NCT06406114
View directory record Official record
Conditions
Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions
Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study to Determine a Preference for Fluzone Vaccine Given Intradermally (ID) and Intramuscularly (IM) in Healthy Adults

NCT00623181
View directory record Official record
Conditions
Influenza
Interventions
Fluzone: Influenza virus vaccine
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years to 49 Years
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
Grove City, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Comparison of Delivery Routes of Flu Vaccine in Adults

NCT00170547
View directory record Official record
Conditions
Influenza
Interventions
Trivalent inactivated influenza vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 64 Years
Enrollment
1,597 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
10
States / cities
Stanford, California • Torrance, California • Iowa City, Iowa + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Bacille Calmette-Guerin (BCG) Vaccine for Immune Protection Against Infections

NCT04884308
View directory record Official record
Conditions
Cystic Fibrosis, Bronchiectasis Adult, Non-Tuberculous Mycobacteria
Interventions
BCG TICE Vaccine
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 1 Interventional

Autologous Tumor DRibble Vaccine in Patients With Non-Small Cell Lung Cancer

NCT00850785
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
DRibble vaccine
Biological
Lead sponsor
Providence Health & Services
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Trial of DAR-901

NCT02063555
View directory record Official record
Conditions
Tuberculosis
Interventions
DAR-901, BCG, Sterile saline
Biological
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Oct 15, 2026, 3:21 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

NCT04251117
View directory record Official record
Conditions
HCC
Interventions
GNOS-PV02, INO-9012, Pembrolizumab, CELLECTRA®2000 EP Device
Biological · Drug · Device
Lead sponsor
Geneos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 2 Interventional

Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

NCT01058785
View directory record Official record
Conditions
Lung Neoplasm, Carcinoma, Bronchogenic
Interventions
Lucanix
Biological
Lead sponsor
NovaRx Corporation
Industry
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
3
States / cities
Newport Beach, California • Metairie, Louisiana • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Nonirritating Concentrations of Midazolam, Ketamine, and Ondansetron

NCT07103720
View directory record Official record
Conditions
Allergy
Interventions
Skin Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 15, 2026, 3:21 PM EDT
Completed Phase 1 Interventional

A Phase I Clinical Trial of Autologous Dendritic Cell Vaccine for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00683241
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
DCVac-L
Biological
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2013 · Synced Oct 15, 2026, 3:21 PM EDT
Terminated Phase 2 Interventional Results available

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

NCT02978222
View directory record Official record
Conditions
Platinum Sensitive Ovarian Cancer, Ovarian Cancer
Interventions
FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone
Biological · Drug
Lead sponsor
Marker Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2022 · Synced Oct 15, 2026, 3:21 PM EDT